{
    "root": "30216db9-3d16-e139-e063-6294a90a5867",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Anastrozole",
    "value": "20250312",
    "ingredients": [
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "ANASTROZOLE",
            "code": "2Z07MYW1AZ"
        }
    ],
    "indications": "anastrozole aromatase inhibitor indicated : adjuvant treatment postmenopausal women hormone receptor-positive early breast cancer ( 1.1 ) first-line treatment postmenopausal women hormone receptor-positive hormone receptor unknown locally advanced metastatic breast cancer ( 1.2 ) treatment advanced breast cancer postmenopausal women disease progression following tamoxifen therapy . patients er-negative disease patients respond previous tamoxifen therapy rarely responded anastrozole ( 1.3 )",
    "contraindications": "one 1 mg tablet taken daily ( 2.1 )",
    "warningsAndPrecautions": "anastrozole tablets , usp 1 mg supplied bottles 30 tablets ( ndc 24979-725-06 ) , bottles 90 tablets ( ndc 24979-725-07 ) .",
    "adverseReactions": "patients demonstrated hypersensitivity anastrozole tablets excipient ( 4 )",
    "indications_original": "Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole\u00a0 ( 1.3 )",
    "contraindications_original": "One 1 mg tablet taken once daily ( 2.1 )",
    "warningsAndPrecautions_original": "Anastrozole Tablets, USP 1 mg are supplied in bottles of 30 tablets (NDC 24979-725-06), bottles of 90 tablets (NDC 24979-725-07) .",
    "adverseReactions_original": "Patients with demonstrated hypersensitivity to anastrozole tablets or any excipient ( 4 )"
}